Charles River Laboratories (CRL) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Strategic framework and efficiency
CEO introduced Pathway to Purpose, focused on modernization, portfolio refinement and client centricity to support competitiveness over the next 3 years, 5 years and beyond.
Create the Future targets $300M in cost savings over the next 3 years, following $300M taken out over the prior 3 years; expected margin improvement is ~75 bps over the next few years.
Modernization aims to make processes more scalable, automated and digital; an automated Microbial Solutions production line increased capacity 14%.
Apollo Orchestrate will digitize Biologics Testing workflows from sample submission through lab work and reporting, including data organization and AI use.
Portfolio and client relationships
Divested European early discovery assets and the CDMO business together with cell supply; acquired a non-human primate facility to integrate supply and support timely critical safety studies.
PathoQuest acquisition adds NAMs technology intended to replace in vivo testing in Biologics Testing and cell-bank characterization, reducing a normal 20-week process by 40%.
Signed a primary strategic partnership with a top-10 pharmaceutical company; leadership cited stronger client access and reliable service as priorities for long-term shareholder value.
Demand, pricing and growth outlook
Demand improved across biotech and global biopharma; proposal rates rose high-single to high-double digits YoY for five consecutive months, while book-to-bill gains spanned both client segments.
Early-stage funding and company formation remain areas to monitor; biotech funding was lower in Q3 but appeared stable again in Q4.
Pricing increases are beginning after strategic discounting during 2024-25; capture rates remained up, but revenue realization may take a few quarters as lower-priced backlog is worked through.
DSA long-range growth target is 5%-7%, based on visible demand and client pipelines; AI-driven demand and further pricing could add upside, while biotech funding remains a key risk to the range.
Latest events from Charles River Laboratories
- Organic growth and DSA demand lifted results and FY26 guidance.CRL
Q3 2026 - 2030 targets: 5%–7% organic revenue CAGR, ~24% margin, and $300M+ in cost savings.CRL
Investor Day 2026 - Strong bookings, operational modernization, and supply chain investments drive margin growth.CRL
2026 Global Healthcare Conference - Demand and bookings are rising, with strategy and portfolio set for growth and margin expansion.CRL
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 saw raised guidance, strong segment margins, and organic revenue growth despite divestiture losses.CRL
Q2 2026 - Robust demand, cost discipline, and innovation drive stable margins and long-term growth.CRL
Morgan Stanley 23rd Annual Global Healthcare Conference - Strategic review advances as stable core businesses offset biotech funding headwinds.CRL
Baird Global Healthcare Conference 2025 - 2026 guidance projects margin improvement and EPS growth despite flat revenue.CRL
Q4 2025 - Non-GAAP EPS up 3.1% and 2025 guidance raised despite revenue decline and regulatory risks.CRL
Q1 2025